Aimmune Therapeutics Company Profile (NASDAQ:AIMT)

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.05. View Aimmune Therapeutics' Earnings History.

Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 8th 2017. View Earnings Estimates for Aimmune Therapeutics.

4 brokerages have issued twelve-month price objectives for Aimmune Therapeutics' stock. Their predictions range from $30.00 to $42.00. On average, they anticipate Aimmune Therapeutics' stock price to reach $36.25 in the next twelve months. View Analyst Ratings for Aimmune Therapeutics.

Here are some recent quotes from research analysts about Aimmune Therapeutics stock:

• 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (7/27/2017)
• 2. Piper Jaffray Companies analysts commented, "Today Aimmune reported 4Q16 financial results, ending the quarter with $249M in cash. We think this cash funds the company through at least YE18. By this time, we should have results from its Phase III PALISADE program in peanut allergy and we see compelling efficacy as well as safety here as the key value-creating event for AIMT shares around YE17/early '18. By YE18, we also expect a BLA filing submitted for use in kids and teens. Based on guidance of BLA timing, and assuming the full year for BLA prep, filing and review (despite the BTD status granted to AR101), we're modestly adjusting first US peds/teens sales from 2019 to 2020, resulting in a new PT of $38. Despite this change, we continue to recommend AIMT in advance of 12-month clinical progress including, importantly, PALISADE up-dosing completion around mid'17 which we see as potentially reducing clinical risk for the program." (3/15/2017)

Some companies that are related to Aimmune Therapeutics include Supernus Pharmaceuticals (SUPN), Advanced Accelerator Applications S.A. (AAAP), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), NOVAN INC (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).

Aimmune Therapeutics' management team includes the folowing people:

• Mark D. McDade, Independent Chairman of the Board
• Stephen G. Dilly M.D. Ph.D., President, Chief Executive Officer, Director
• Eric H. Bjerkholt, Chief Financial Officer
• Jeffrey H. Knapp, Chief Operating Officer
• Susan E. Barrowcliffe, Senior Vice President, General Manager of Europe
• Mary M. Rozenman, Senior Vice President - Strategy and Corporate Development
• Douglas T. Sheehy J.D., General Counsel, Secretary
• Sue Barrowcliffe, General Manager of Europe
• Daniel C. Adelman M.D., Chief Medical Officer
• Greg Behar, Independent Director

(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

Aimmune Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Emerald Advisers Inc. PA (1.11%), Emerald Mutual Fund Advisers Trust (0.91%), Strs Ohio (0.07%), Russell Investments Group Ltd. (0.05%), Franklin Street Advisors Inc. NC (0.02%) and Daiwa SB Investments Ltd. (0.01%). Company insiders that own Aimmune Therapeutics stock include Douglas T Sheehy, Eric Bjerkholt, Foresite Capital Fund Ii, LP, Longitude Capital Partners Ii,, Mary M Rozenman, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.

Aimmune Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers Inc. PA, Franklin Street Advisors Inc. NC, Russell Investments Group Ltd. and Daiwa SB Investments Ltd.. Company insiders that have sold Aimmune Therapeutics stock in the last year include Douglas T Sheehy, Mary M Rozenman, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Insider Buying and Selling for Aimmune Therapeutics.

Aimmune Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Eric Bjerkholt and Longitude Capital Partners Ii,. View Insider Buying and Selling for Aimmune Therapeutics.

Shares of Aimmune Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Aimmune Therapeutics stock can currently be purchased for approximately $21.60.